"Completion of enrollment in the first cohort of the Phase 1b MAD study is an important milestone in the development of this novel treatment for ADPKD," sa...
OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab (anti-PD1 mAb) in...
After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists...
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) fo...
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), announced that the U.S. Food and Drug Admini...
Conventional high-content screening experiments typically focus on extracting imaging data relating to predefined, specific features to identify drugs or d...
The rising prevalence of chronic diseases coupled with increasing research activities for cell-based research is found to be the major factor driving the...
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, ...
Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases announced today that the ...
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- -Vertex Pharmac...
Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new data, covered by its previously filed patents, demonstrati...
“We are excited to begin working with Moderna on a specific application of our AI-enabled cryo-EM platform that leverages our technology infrastructu...
Under the terms of the agreement, Xeris will use its proprietary drug-formulation platform, XeriJect™, to develop ultra-highly concentrated, ready-to...
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control Travere Therapeutics, Inc. (...
© 2025 Biopharma Boardroom. All Rights Reserved.
